Ligand Pharmaceuticals (NASDAQ:LGND – Get Rating) had its target price upped by HC Wainwright from $135.00 to $144.00 in a report released on Friday, The Fly reports. Other equities analysts also recently issued reports about the company. StockNews.com raised Ligand Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, […]
Related Keywords
Chicago ,Illinois ,United States ,Johnw Kozarich , ,Ziegler Capital Management ,News Ratings For Ligand Pharmaceuticals Daily ,Ligand Pharmaceuticals Inc ,Institutional Investors Weigh In On Ligand Pharmaceuticals ,Pacer Advisors Inc ,Ligand Pharmaceuticals Stock ,Chicago Capital ,Norges Bank ,Ligand Pharmaceuticals ,Insider Activity At Ligand Pharmaceuticals ,Get Rating ,Director John ,Capital Management ,Pictet Asset Management ,Ligand Pharmaceuticals Daily ,Nasdaq Lgnd ,Lgnd ,Medical ,53220k50 ,Boost Price Target ,Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.